Next |
home / stock / rvxcf / rvxcf message board
Subject | By | Source | When |
---|---|---|---|
Anyone have any idea what this company is | big orange | investorshub | 07/16/2020 5:32:26 PM |
With all that has been shown in the | cabel | investorshub | 04/21/2020 3:01:14 PM |
I think the only plan is survival. | noretreat | investorshub | 04/21/2020 2:45:10 PM |
Any news about the future plans for this company? | big orange | investorshub | 04/21/2020 2:37:04 PM |
69 cents. tempting, but holding off on | noretreat | investorshub | 03/12/2020 7:18:24 PM |
some will use this pop as an exit | noretreat | investorshub | 02/03/2020 4:17:21 PM |
Yes! Much quicker than expected! | cabel | investorshub | 02/03/2020 1:44:11 PM |
BRIEF-Resverlogix Receives US FDA Breakthrough Therapy Designation For Apabetalo | noretreat | investorshub | 02/03/2020 12:40:17 PM |
But it doesnt really matter what the analyst | noretreat | investorshub | 02/02/2020 7:33:37 PM |
As far as I can tell so far | noretreat | investorshub | 02/02/2020 7:33:00 PM |
What do analysts say about the secondary analysis? | big orange | investorshub | 02/01/2020 9:57:08 PM |
Seeing a clear path to commercialization at the | jstiltz22 | investorshub | 01/13/2020 5:19:24 PM |
Interesting secondary analysis released today | noretreat | investorshub | 01/13/2020 3:39:19 PM |
The sad truth is that BetOnMace was a | noretreat | investorshub | 12/13/2019 10:48:47 PM |
The statement in this release was optimistic to | noretreat | investorshub | 12/11/2019 9:38:59 PM |
This ones down about 40% the last couple | noretreat | investorshub | 12/11/2019 9:37:45 PM |
Resverlogix Announces Change to its Board of Directors CALGARY, | Phoenix300 | investorshub | 12/11/2019 1:32:47 PM |
cognitive results pres. | noretreat | investorshub | 12/06/2019 1:50:49 PM |
ambiguous but holy cow!!! | noretreat | investorshub | 12/06/2019 1:51:07 AM |
Thanks. Time will tell. | big orange | investorshub | 12/01/2019 6:59:04 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET Developing safe, epigenetic therapeutics for people suffering from chronic illnesses Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions...
2024-03-27 17:08:02 ET The future of drug development Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses on advancing their lead compound ( apabetalone) and evaluating its th...
Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said ...